Background Angiotensinogen (AGT) T174M gene polymorphism has been suggested to be linked to risk of coronary artery disease, however, results from studies of this association have been inconsistent. In this study, we assess the relationship between AGT T174M gene polymorphism and coronary artery disease. Methods We conducted a meta-analysis of 18 case-control studies with 8,147 coronary artery disease cases and 5,344 controls in Google scholar, PubMed, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases to identify eligible studies published by July, 2012. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated from these studies. Results Overall, a significant association was found between angiotensinogen T174M polymorphism and coronary artery disease risk when all studies were pooled into the meta-analysis ( 
Introduction
Coronary artery disease (CAD) continues to be a major cause of morbidity and mortality among adults in both Europe and North America. [1] Projections show that by 2030 an additional eight million people could have CAD, a 16.6% increase in prevalence from 2010 in the United States. [2] In 2008, the overall CAD death rate was 122.7 per 100,000 population. From 1998 to 2008, the annual death rate due to CAD declined 28.7%, and actual number of deaths declined 11.9%. In the United States, the death rate was 161.7 for white males and 183.7 for black males, while the rate was 91.9 for white females and 115.6 for black females. [3] A study found that previous CAD risk factor exposures were common among those who developed CAD. About 90% of patients with CAD have prior exposure to at least one of the major risk factors, which include high total blood choles- terol level or current medication with cholesterol-lowering drugs, hypertension or current medication with blood pressure-lowering drugs, current cigarette use, or a clinical report of diabetes. [4] There is increasing evidence that gene-environment interaction plays a vital role in the genetic studies of complex trait diseases. Human angiotensinogen (AGT) is produced by the liver and changed to angiotensin I via renin. Afterwards, angiotensin I is converted to angiotensin II, which leads to myocardial hypertrophy, fibrosis and vasoconstriction. The AGT gene is located at lq42-43 and consists of five exons. [5] A threonine to methionine substitution at amino acid 174 is a common polymorphism called T174M (rs699), designating the T and M alleles, respectively. [6] Over the past decade, the AGT gene T174M polymorphism has been investigated for its association with the risk of developing CAD. Tiret et al. [7] were the first to investigate the association between AGT T174M polymorphism and myocardial infarction (MI), the study population comprised 630 cases and 741 controls. The result showed that the T174M genotype distribution did not differ between the case group and control group, and they did not find a significant association between T174M and CAD risk. [7] Later, several studies, but not all, confirmed the relationship between AGT http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology T174M polymorphism and susceptibility to CAD. Metaanalysis is a useful tool to evaluate rare allele frequency polymorphisms. [7] The present meta-analysis was conducted to obtain a more precise estimation of the associations between AGT T174M gene polymorphism and CAD.
Methods

Selection of studies
Google scholar, PubMed, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases were searched for all articles on the association between AGT T174M polymorphism and CAD risk available before July, 2012 without language restrictions, using the following key words: "angiotensinogen", "myocardial infarction", "coronary heart disease", "coronary artery disease", "gene" and "T174M polymorphism." Only articles that had complete data on the comparison of T174M polymorphism frequency between CAD and control were selected in our meta-analysis. Reference lists of review articles and included articles were identified through hand searches to find other potentially eligible papers. The criteria includes: CAD, ischemic heart disease and atherosclerotic heart disease.
Selection criteria
To be eligible for inclusion in this meta-analysis, the following criteria were established: (1) case-control study design; (2) studies were conducted to evaluate the association between AGT T174M polymorphism and CAD risk; (3) studies that included sufficient genotype data to calculate the Odds ratios (OR) and 95% confidence intervals (95% CI); and (4) genotype distributions of healthy control population were in Hardy-Weinberg equilibrium (HWE). Major reasons for exclusion were: (1) not case-control studies that evaluated the association between AGT T174M polymorphism and CAD risk; (2) case reports, letters, reviews, and editorial articles; (3) no sufficient data were reported; (4) duplicate data; and 5) healthy controls were not in HWE.
Data extraction
The following characteristics were collected from each study: first author, year of publication, country, gender, end point of assessment, number of cases and controls, polymorphisms of gene, and evidence of HWE of controls. For conflicting evaluations, investigators came to an agreement after discussion.
Statistical analysis
Meta-analysis was performed using the STATA software 2 test were performed to probe whether the variation was due to heterogeneity or sampling error (chance). Values for I 2 of 25%, 50% and 75% were defined as low, moderate and high estimates, respectively. [8] We used fixed-effects methods if the result of the Q-test was not significant (P > 0.10 or I 2 < 50%).
Otherwise, the random-effects model was used for pooling all the results. We tested whether genotype frequencies of controls were in HWE using the Pearson χ 2 test and a P < 0.05 was considered as significant disequilibrium. Subgroup analysis was performed according to ethnicity, CAD subtypes, and gender. The different ethnicities were categorized as Asians and Caucasians. Begg's funnel plot was used to assess publication bias (P < 0.05 was considered statistically significant). Sensitivity analysis was performed by sequential omission of individual studies to ensure the stability of measuring results. All P values were two-sided.
Results
Characteristics of studies
There were 495 papers relevant to the search words. Based on the inclusion criteria, only eighteen case-control studies were selected for this meta-analysis, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and 477 studies were excluded. The flow chart of the study selection is summarized in Figure 1 . These selected studies included 8,147 CAD cases and 5,344 healthy controls. All studies were case-control studies that evaluated the association between AGT T174M polymorphism and CAD risk. The genotype distributions among the controls of all studies aiming at AGT T174M polymorphism were consistent with HWE (Table 1 , P > 0.05). The study selection and subject characteristics are summarized in Table 1 . Of these casecontrol studies, nine reported on Caucasians, [9, 10, [16] [17] [18] [19] [24] [25] [26] while the other reports were on Asians.
Results of meta-analysis
The combined results of AGT T174M polymorphism and CAD risk are summarized in Table 2 (Figure 2 ). In addition, no statistical association was found in other stratified analyses (Figure 2 ). Sensitivity analysis was performed by sequential omission of individual studies. The significance of pooled OR in all individual analyses and subgroup analyses was not excessively influenced by omitting any single study. Publication bias of the literature was assessed by the Begg test. The results are shown in Table 2 and Figure 3 . 
Discussion
The renin-angiotensin system is one of the major regulators of blood pressure and cardiovascular homeostasis. AGT is an important component of renin-angiotensin system. AGT is a precursor of angiotensin II, which causes drastic vasoconstriction and stimulates proliferation of vascular muscle cells and cardiomyocytes. Many studies have evaluated the relationship of AGT T174M polymorphism with CAD risk, but the above observed associations consisted of a small number of samples, and the results may reflect chance observations rather than true associations. A previous meta-analysis in 2007 conducted by Xu, et al. [27] investigated the relationship between T174M and CAD risk in sixteen studies, which did not support an association between the T174M polymorphism and susceptibility to CAD. However, there was no stratified analysis to estimate the relationship between T174M/M235T polymorphism and risk of CAD. [27] Hence, the results might have been affected by ethnicity or end point of assessment differences. Our meta-analysis assessed the association between T174M polymorphism and the susceptibility to CAD by subgroup analysis. The results of the meta-analysis indicated T174M polymorphism may be a potential risk factor for CAD in Caucasians. However, Table 2 and Figure 3 shows evidence for publication bias (P < 0.05), when we perform a subgroup analysis with CAD aiming at coronary stenosis and MI. However, the results of the Begg's funnel plot test showed that there was no publication bias, and the data led us to the conclusion that the heterogeneity was closely related to end point of CAD. Furthermore, we need to point out that T174M polymorphism may be related to Caucasian patients with coronary stenosis, not MI. The results agree with the latest studies that the occurrence of MI and coronary atherosclerosis is due to different genetic variants. [28, 29] In the subgroup analysis by ethnicity, no significant association was found between T174M polymorphism and susceptibility to CAD in Asians, suggesting a possible role of ethnic differences in genetic backgrounds and the environment in which they live. As the eligible study number was small in this meta-analysis of T174M polymorphism, the results still need further investigation. The mechanism of how AGT T174M polymorphism relates to coronary stenosis risk is still unclear. The serum AGT level was shown to be higher in subjects carrying the T allele. [30] AGT interacts with renin to produce angiotensin II.
Angiotensin II activates vascular cell apoptosis, contributing to vascular remodelling and cardiomyocyte loss in ischemia-reperfusion. [31] Furthermore, Angiotensin II has been shown in both human and animal models to be involved in the development of cardiomyocyte hypertrophy, and in cardiac fibrosis, and modulation of cardiac fibroblast growth and collagen synthesis. [32] In addition, the linkage disequilibrium of M235T and T174M in exon 2 of the AGT gene may synergistically increase the risk of CAD. [22] Those evidences suggested that T174M polymorphism might play an important role in the development of coronary stenosis. Several potential limitations of the present study should be noted. First, because of incomplete genotype data [33] or CAD patients with other diseases combined, [34] some relevant studies could not be included in our analysis. Second, the effect of genetic and environmental interactions was not addressed in our meta-analysis. Third, the numerical results may be affected by age, and potentially age-related subgroups could not be reliably investigated because data on individual participants were not available for the metaanalysis.
In conclusion, the results indicate a significant association of AGT T174M polymorphism with coronary stenosis risk in Caucasians. However, further studies of gene-gene and gene-environment interactions should be taken into consideration.
